Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

Background Low trough imatinib concentration ( C min ) values have been associated with poor clinical outcomes in gastrointestinal stromal tumour (GIST) patients. This study describes the pharmacokinetics of imatinib in a large cohort of GIST patients in routine clinical care. Methods An observation...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacokinetics 2017-03, Vol.56 (3), p.287-292
Main Authors: Farag, Sheima, Verheijen, Remy B., Martijn Kerst, J., Cats, Annemiek, Huitema, Alwin D. R., Steeghs, Neeltje
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - blood
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Breast cancer
Cancer therapies
Chromatography
Clinical outcomes
Cohort Studies
Drug dosages
Family medical history
Female
Gastrointestinal cancer
Gastrointestinal Neoplasms - blood
Gastrointestinal Neoplasms - drug therapy
Gastrointestinal Neoplasms - epidemiology
Gastrointestinal Stromal Tumors - blood
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - epidemiology
Humans
Imatinib Mesylate - blood
Imatinib Mesylate - pharmacokinetics
Imatinib Mesylate - therapeutic use
Internal Medicine
Leukemia
Male
Mass spectrometry
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Mutation
Netherlands - epidemiology
Observational studies
Original Research Article
Patients
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Registries
Retrospective Studies
Scientific imaging
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Low trough imatinib concentration ( C min ) values have been associated with poor clinical outcomes in gastrointestinal stromal tumour (GIST) patients. This study describes the pharmacokinetics of imatinib in a large cohort of GIST patients in routine clinical care. Methods An observational study was performed in imatinib-treated GIST patients. Patient and tumour characteristics were derived from the Dutch GIST Registry and medical records. Imatinib concentrations were measured by liquid chromatography with tandem mass spectrometry. The analyses included the occurrence of a low imatinib C min (
ISSN:0312-5963
1179-1926
DOI:10.1007/s40262-016-0439-7